Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GIP, GLP-1, and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT06194955Completed
- Sponsor
- University of Copenhagen
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of glucose-dependent insulinotropic polypeptide[1-42], Glucagon-like peptide 1 and glucagon-like peptide-2 (6 arms), sponsored by University of Copenhagen. Primary endpoints: Insulinotropic effect (C-peptide) at 240 minutes and CTX (bone resorption marker) at 120 minutes. Started Jan 2023; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]Glucagon-like peptide 1glucagon-like peptide-2
Beyond the preview
Go deeper on NCT06194955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194955.